Richard Kim, MD,

Articles

Dr. Kim on the Safety Profile of Atezolizumab/Bevacizumab in HCC

September 14th 2020

Richard D. Kim, MD, discusses the safety profile of the combination of atezolizumab and bevacizumab in hepatocellular carcinoma.

Dr. Kim on the Evolving Treatment Landscape of Advanced HCC

August 14th 2020

Richard D. Kim, MD, discusses the evolving treatment landscape of advanced hepatocellular carcinoma.

Dr. Kim on Efficacy and Next Steps With Regorafenib/Nivolumab Combo in CRC

July 3rd 2020

Richard D. Kim, MD, discusses the efficacy of and next steps for a phase 1/1b study with regorafenib and nivolumab in patients with mismatch repair proficient advanced refractory colorectal cancer.

Dr. Kim on Immunotherapy in CRC

December 18th 2019

Richard Kim, MD, discusses the use of immunotherapy in colorectal cancer.

Dr. Kim on Optimizing Outcomes With Molecular Profiling in mCRC

December 13th 2019

Richard Kim, MD, discusses how molecular profiling can be used to optimize outcomes in patients with metastatic colorectal cancer.

Dr. Kim on Treatment for BRAF-Mutant Colon Cancer

November 16th 2019

Richard Kim, MD, discusses treatment options for BRAF-mutant colon cancer.

Dr. Kim on the Potential of Ramucirumab in Advanced HCC

April 26th 2019

Richard Kim, MD, assistant professor of oncology at University of South Florida College of Medicine, medical oncologist in the Department of Gastrointestinal Oncology at Moffitt Cancer Center, discusses the potential of ramucirumab in the treatment of advanced hepatocellular carcinoma.

Dr. Kim on Role of Frontline Immunotherapy in Advanced HCC

April 8th 2019

Richard Kim, MD, assistant professor of oncology, University of South Florida College of Medicine, medical oncologist, Department of Gastrointestinal Oncology, Moffitt Cancer Center, discusses the role of frontline immunotherapy in patients with advanced hepatocellular carcinoma.

Dr. Kim on Administering Aflibercept in mCRC

February 19th 2013

Richard Kim, MD, medical oncologist, Gastrointestinal Oncology Department at Moffitt Cancer Center, discusses the use of ziv-aflibercept (Zaltrap) for patients with metastatic colorectal cancer.

Dr. Kim on the Investigation of Regorafenib in mCRC

January 31st 2013

Richard Kim, MD, medical oncologist, Gastrointestinal Oncology Department at Moffitt Cancer Center, discusses studies investigating regorafenib (Stivarga) in metastatic colorectal cancer.

x